| |
| 2009 |
|
|
| March |
Internet Innovator from Silicon Valley, Prof. Michael A. Keller, Stanford University,
joins the Mondobiotech Board of Directors |
President of the Swiss Cancer League Prof. Thomas Cerny, St. Gallen University,
joins the Mondobiotech Board of Directors |
| January |
23andME and Mondobiotech Partner to Advance Research on Rare Diseases
We partnered with 23andMe (genetic company invested by Google, Inc. and other investors)
to advance genetic research for patients in rare diseases |
| 2008 |
|
|
Mondobiotech recepient of The Swiss Innovation Award 2008
by the Central Swiss Chamber of Commerce |
| November |
Beneficial effects of inhaled Aviptadil in patients with chronic pulmonary hypertension
published in The European Respiratory Journal (2008 Nov;32(5):1289-94) |
Mondobiotech granted the leasehold on the former Capuchin monastery in Stans (Switzerland)
as headquarter and research institute |
| Mondobiotech patented more than 300 medicinal product candidates for rare diseases |
| 2007 |
|
|
SOUTHERN RESEARCH
Agreement with Southern Research Institute for biological screening of 312 peptides |
IFE
Business alliance with IFE Europe GmbH, a company owned by Pierrel S.p.A.,
for clinical study management |
LUNGRX/UNITED THERAPEUTICS
LungRx and Mondobiotech, signed a transatlantic strategic partnership agreement
for developing drugs |
| Mondobiotech selected as Technology Pioneer 2008 by the World Economic Forum |
| Mondobiotech started Campus educations on rare diseases for clinical experts around the world |
EMEA
Orphan Medicinal Product Designation for Aviptadil in Sarcoidosis (EU/3/07/473) |
| Mondobiotech selected as Best Innovator 2007 |
| 2006 |
|
|
| Chief Business Architect Fabio Cavalli Start-up Swiss Entrepreneur of the Year 2006 |
| August |
EMEA
EMEA Orphan Medicinal Product Designation for Aviptadil in Acute Lung Injury (ALI)
(EU/3/06/395) received 28/08/2006 |
| Collaboration and Licensing out agreement with Biogen Idec for Aviptadil in PAH |
NEBU-TEC
Agreement with Nebu-Tec for inhalative treatments in orphan diseases |
| Official opening of the Hardhof Basel Mondobiotech’s Headquarters |
QUINTILES
Business Alliance with Quintiles for management of Mondobiotech’s clinical trials |
BACHEM
Exclusive access to Bachem Peptide Library to screen for new projects |
| 2005 |
|
|
EMEA/FDA
Parallel Advice Protocol Review for Aviptadil in PAH Phase III |
| Winner of the Swiss Life Sciences Prize 2005 |
| Prof. Dr. Robert Huber, Nobel laureate, appointed to Mondobiotech’s Board of Directors |
| June |
Interferon gamma patent (EP 0 795 332 B1) for: “Medical use of Gamma Interferon
in Interstitial Lung Diseases” received 01/06/2005 |
FDA
Orphan drug status designation for Aviptadil in ARDS received 01/06/2005 |
| May |
EMEA
Orphan drug status designation (EU/3/05/281) for Interferon gamma
in IPF received 30/05/2005 |
BACHEM
Collaboration agreement for production & supply of Thymopentin for studies
in different orphan indications |
| February |
FDA
Orphan drug status designation for Aviptadil in PAH received 22/02/2005 |
| 2004 |
|
|
| Mondobiotech opens offices in Basel, Switzerland |
| 2003 |
|
|
EMEA
Orphan Drug Status for Aviptadil in PAH and CTEPH EU/3/03/173 received 23/12/2003 |
BACHEM
Exclusive licensing agreement for manufacturing Aviptadil for studies
in different orphan indications |
| 2002 |
|
|
| Aviptadil results in PPH published |
INTERMUNE
Licencing agreement for IFN-γ in IPF and Asthma |
| 2001 |
|
|
| February |
Mondobiotech is started immediately after the human genome is deciphered
on the ground-floor of Vera’s house |
